For the enhanced delivery of drugs ranging from potent anticancer therapeutics to large recombinant proteins, Aphios Corporation has developed and patented several enabling nanotechnologies [U.S. and International Patents]:

• Protein Nanoparticles: Based on a SuperFluids™ rapid expansion mechanism, protein nanoparticles for enhanced drug delivery of protein macromolecules can be generated without reduction in protein integrity and efficacy in a solvent-free process.  This technology can be used for pulmonary delivery of proteins and polypeptides such as insulin for diabetes; and oral/depot delivery of vaccine antigens.

• Polymer Nanospheres: Through reverse engineering of the rapid expansion mechanism, biodegradable polymeric nanospheres for the controlled delivery and release of proteins can be manufactured utilizing SuperFluids™ technologies.  This technology can be used for oral/depot delivery of proteins such as calcitonin for osteoporosis and controlled-release adjuvants of vaccine antigens for infectious diseases.

• Phospholipid Nanosomes: By a similar mechanism, phospholipid nanosomes (small uniform liposomes) for the enhanced delivery of water-soluble (hydrophilic) drugs and water-insoluble (hydrophobic) drugs can be produced without the use of toxic organic solvents. This technology can be used for intravenous and/or topical administration of small hydrophilic molecules, proteins and genes, and hydrophobic anticancer drugs such as paclitaxel and camptothecin.

These technologies are available for licensing on a product-specific basis to strategic corporate partners.  Aphios will provide technology support as well as research and manufacturing units. We will also establish development and commercialization partnerships utilizing Aphios’ proprietary drug delivery nanotechnologies, out-license enhanced natural therapeutics such as Taxosomes™, and conduct contract R&D such as that recently conducted for a multinational pharmaceutical company on the manufacturing of solvent-free polymer microspheres for protein delivery.

Aphios has utilized these technologies to develop several enhanced therapeutic products.  For more information on the application of these enabling nanotechnologies to your pharmaceutical and/or biotechnology products, contact Dr. Trevor P. Castor at aphios@aol.com.

Home l Company | Infectious Diseases | Oncology | Nutraceuticals | Product Pipeline | Purchase Products | Technology Platforms | Equipment |Patents | Press Releases | Contact Aphios